AKBA vs. ARQT, INDV, AKRO, GLPG, DYN, IMCR, EVO, GPCR, VIR, and TVTX
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Arcutis Biotherapeutics (ARQT), Indivior (INDV), Akero Therapeutics (AKRO), Galapagos (GLPG), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Structure Therapeutics (GPCR), Vir Biotechnology (VIR), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.
Akebia Therapeutics vs.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
Akebia Therapeutics has higher revenue and earnings than Arcutis Biotherapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
33.9% of Akebia Therapeutics shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 4.1% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Akebia Therapeutics received 353 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 65.26% of users gave Arcutis Biotherapeutics an outperform vote while only 63.55% of users gave Akebia Therapeutics an outperform vote.
Akebia Therapeutics has a net margin of -27.07% compared to Arcutis Biotherapeutics' net margin of -140.97%. Akebia Therapeutics' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.
Arcutis Biotherapeutics currently has a consensus target price of $16.60, indicating a potential upside of 30.91%. Akebia Therapeutics has a consensus target price of $7.50, indicating a potential upside of 262.32%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Arcutis Biotherapeutics.
Arcutis Biotherapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.
In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 17 mentions for Arcutis Biotherapeutics and 15 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.66 beat Arcutis Biotherapeutics' score of 0.50 indicating that Akebia Therapeutics is being referred to more favorably in the news media.
Summary
Akebia Therapeutics beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akebia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AKBA) was last updated on 1/18/2025 by MarketBeat.com Staff
Free AKBA Stock Alerts